An interventional study of Brain Health Assessment in Dementia and Alzheimer Disease, sponsored by University of California, San Francisco. Completed at 3 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by University of California, San Francisco — 3 open to participants now, 5 under way, none of them phase 3. Alzheimer Disease · University of California, San Francisco.
Among the 17 studies in Alzheimer Disease by University of California, San Francisco, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 13 with no phase, and was the 14th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →3 of the 17 studies in Alzheimer Disease by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 65+
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 60+ · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,261 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 66 across the 15 interventional studies, 100,030 across the 2 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Alzheimer Disease by University of California, San Francisco, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The eRADAR Brain Health Study is an embedded, pragmatic clinical trial to determine whether targeted screening for dementia using the eRADAR algorithm increases dementia detection within primary care compared to usual care.
eRADAR stands for "electronic health record (EHR) Risk of Alzheimer's and Dementia Assessment Rule." It is a low-cost tool or algorithm that uses readily available EHR data elements to identify patients at risk of undiagnosed dementia. The investigators will conduct a pragmatic randomized controlled trial to assess the impact of implementing eRADAR as part of a supported outreach process on dementia detection rates. The investigators will also explore the impact of eRADAR implementation on healthcare utilization and patient experience.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
This study's enrollment of 1,261 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Currently receiving hospice care
Participants in the intervention arm were invited to attend a "brain health" visit with a trained research interventionist who was a licensed clinician (e.g., social worker.) They were sent a mailed outreach letter and information sheet, with follow-up phone calls. At the visit, the research interventionist asked about memory symptoms and ability to perform instrumental activities of daily living (IADLs) and screened for cognitive impairment and depression. Results were shared with the participant and their primary care physician (PCP), who was responsible for follow up and more evaluation if needed and for making a final diagnosis of dementia, if applicable.
Other: Brain Health Assessment
Individuals in this arm did not receive any intervention but rather usual care. University of California, San Francisco (UCSF) does not routinely screen for cognitive impairment (in line with current guidelines from the US Preventive Services Task Force).
Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
New Diagnoses of Dementia (12 Months)
Number of patients who received new dementia diagnoses within 12 months, identified from the electronic health record (EHR) using a prespecified set of ICD-10 codes
Time frame: 12 months after index date
New Diagnoses of Dementia or Mild Cognitive Impairment (12 Months)
Number of patients who received a new diagnosis of dementia or mild cognitive impairment within 12 months, defined from EHR data
Time frame: 12 months after index date
New Diagnoses of Dementia (18 Months)
Number of patients who received a new diagnosis of dementia within 18 months of index date, defined from EHR data
Time frame: 18 months after index date
New Diagnoses of Dementia (6 Months)
Number of patients receiving new dementia diagnoses within 6 months of index date, defined using EHR data
Time frame: 6 months after index date
New Dementia Medications (12 Months)
Number of patients who received a new medication for dementia in 12 months, defined from medication orders or dispensings in the electronic health record
Time frame: 12 months after index date
Urgent Care or Emergency Department Visits (12 Months)
Number of patients who had at least 1 urgent care or emergency department visit in the 12 months following their index date
Time frame: 12 months after index date
Hospitalizations and Inpatient Admissions (12 Months)
Average number of hospitalizations and inpatient stays per participant within 12 months of index date
Time frame: 12 months after index date
Scheduled Visits Missed (12 Months)
Average number of scheduled clinic visits missed ("no shows") per participant
Time frame: 12 months after index date
Primary Care Visits (6 Months)
Average number of visits per participant in primary care within 6 months after the index date
Time frame: 6 months after index date
Primary Care Visits (12 Months)
Average number of primary care visits per participant in the 12 months after their index date
Time frame: 12 months after index date
B-12 Lab Tests (12 Months)
Number of patients with at least one B12 lab test in the 12 months after their index date
Time frame: 12 months after index date
Neuroimaging Tests (12 Months)
Number of patients with at least one neuroimaging study (CT head, MRI brain) in the 12 months after their index date
Time frame: 12 months after index date
Neurology Referrals (12 Months)
Number of patients with at least one referral to Neurology or the Memory and Aging Center in the 12 months after their index date
Time frame: 12 months after index date
A research study programmer extracted EHR data to identify patients who met eligibility criteria within each study clinic. Eligible patients were then randomized in blocks based on their primary care provider to intervention or usual care groups. The date of randomization was used as their initiation date into the study. All patients initiated were followed through the electronic health record for outcomes, except those who were later found to have died prior to the initiation date.
| Milestone | Brain Health Intervention | Usual Care |
|---|---|---|
| Started | 683 | 578 |
| Completed | 681 | 575 |
| Not completed | 2 | 3 |
| Withdrew: Found to have died prior to initiation into study | 2 | 3 |
Number of patients who received new dementia diagnoses within 12 months, identified from the electronic health record (EHR) using a prespecified set of ICD-10 codes
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| New Diagnoses of Dementia (12 Months) | 26 | 21 |
Number of patients who received a new diagnosis of dementia or mild cognitive impairment within 12 months, defined from EHR data
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| New Diagnoses of Dementia or Mild Cognitive Impairment (12 Months) | 69 | 37 |
Number of patients who received a new diagnosis of dementia within 18 months of index date, defined from EHR data
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| New Diagnoses of Dementia (18 Months) | 32 | 30 |
Number of patients receiving new dementia diagnoses within 6 months of index date, defined using EHR data
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| New Diagnoses of Dementia (6 Months) | 10 | 10 |
Number of patients who received a new medication for dementia in 12 months, defined from medication orders or dispensings in the electronic health record
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| New Dementia Medications (12 Months) | 7 | 8 |
Number of patients who had at least 1 urgent care or emergency department visit in the 12 months following their index date
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| Urgent Care or Emergency Department Visits (12 Months) | 217 | 180 |
Average number of hospitalizations and inpatient stays per participant within 12 months of index date
| inpatient stays | Brain Health Intervention | Usual Care |
|---|---|---|
| Hospitalizations and Inpatient Admissions (12 Months) | 0.35 ± 0.92 | 0.28 ± 0.69 |
Average number of scheduled clinic visits missed ("no shows") per participant
| missed visits | Brain Health Intervention | Usual Care |
|---|---|---|
| Scheduled Visits Missed (12 Months) | 0.13 ± 0.51 | 0.16 ± 0.49 |
Average number of visits per participant in primary care within 6 months after the index date
| visits | Brain Health Intervention | Usual Care |
|---|---|---|
| Primary Care Visits (6 Months) | 1.68 ± 1.62 | 1.87 ± 1.82 |
Average number of primary care visits per participant in the 12 months after their index date
| visits | Brain Health Intervention | Usual Care |
|---|---|---|
| Primary Care Visits (12 Months) | 3.26 ± 2.69 | 3.57 ± 2.99 |
Number of patients with at least one B12 lab test in the 12 months after their index date
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| B-12 Lab Tests (12 Months) | 189 | 177 |
Number of patients with at least one neuroimaging study (CT head, MRI brain) in the 12 months after their index date
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| Neuroimaging Tests (12 Months) | 106 | 89 |
Number of patients with at least one referral to Neurology or the Memory and Aging Center in the 12 months after their index date
| Participants | Brain Health Intervention | Usual Care |
|---|---|---|
| Neurology Referrals (12 Months) | 59 | 37 |
Collected over From participant index date to end of follow-up, up to 18 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brain Health Intervention | 53/681 (7.8%) | 239/681 (35.1%) | 78/681 (11.5%) |
| Usual Care | 33/575 (5.7%) | 162/575 (28.2%) | 52/575 (9%) |
| Event | Brain Health Intervention | Usual Care |
|---|---|---|
| HospitalizationsGeneral disorders | 239/681 | 162/575 |
| Event | Brain Health Intervention | Usual Care |
|---|---|---|
| New depression diagnosisPsychiatric disorders | 50/500 | 36/413 |
| New start of antidepressantPsychiatric disorders | 37/429 | 25/345 |
| Suicidal ideationPsychiatric disorders | 3/681 | 0/575 |
| Suicide attemptPsychiatric disorders | 0/681 | 0/575 |
| Age, Continuous(Years) | Brain Health Intervention | Usual Care | Total |
|---|---|---|---|
| Mean | 84.66 ± 5.77 | 84.82 ± 5.67 | 84.73 ± 5.73 |
| Sex/Gender, Customized(Participants) | Brain Health Intervention | Usual Care | Total |
|---|---|---|---|
| Female | 361 | 346 | 707 |
| Male | 319 | 229 | 548 |
| Non-binary | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Brain Health Intervention | Usual Care | Total |
|---|---|---|---|
| Asian | 234 | 171 | 405 |
| Black or African American | 58 | 62 | 120 |
| Hispanic or Latino (any race) | 58 | 56 | 114 |
| White | 299 | 250 | 549 |
| Another or More Than One Race | 28 | 30 | 58 |
| Unknown or not reported | 4 | 6 | 10 |
| Elixhauser comorbidity score(score on a scale) | Brain Health Intervention | Usual Care | Total |
|---|---|---|---|
| Mean | 7.23 ± 8.51 | 7.15 ± 8.04 | 7.19 ± 8.29 |
| eRADAR score(Score on a scale) | Brain Health Intervention | Usual Care | Total |
|---|---|---|---|
| Mean | 0.06 ± 0.04 | 0.06 ± 0.04 | 0.06 ± 0.04 |
| Prior diagnosis of mild cognitive impairment(Participants) | Brain Health Intervention | Usual Care | Total |
|---|---|---|---|
| Count of participants | 20 | 26 | 46 |
| Prior diagnosis of memory problem or concern(Participants) | Brain Health Intervention | Usual Care | Total |
|---|---|---|---|
| Count of participants | 75 | 62 | 137 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — This Individual Participant Data (IPD) plan applies to all quantitative study data, such as data collected specifically for the study and those derived from electronic health records (EHR), as well as the data collected via planned study surveys, which include only short qualitative free-text fields. The investigators do not plan to share transcripts from in-depth qualitative interviews or recorded study assessment visits. Data will be maintained on secure servers behind the firewalls at the University of California, San Francisco (UCSF). De-identified or limited datasets containing individual-level data on which publications are based will be made available to qualified researchers for specified analyses. The investigators will make the data available to users only under a data-use agreement (DUA).
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be requested after the primary study paper is accepted for publication, up until 5 years after study completion.
Access criteria: Individuals interested in using data will be required to complete a standard form, sign a Data Use Agreement (DUA) and provide documentation of IRB approval. User registration will be required in order to access or download data files. As part of the registration process, users must agree to the conditions of use governing access to the data, including restrictions against attempting to identify study participants, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgment of the data resource. The UCSF Industry Contracts Division (ICD), which oversees incoming and outgoing transfer of all UCSF data, will review registration materials for compliance with UCSF policies.
Ran from Dec 2022 to primary completion in Oct 2025, 33 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 33 months is close to that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →